Objective: Intensive chemotherapy targeting plasma cell dyscrasia has been recently employed for the treatment of primary systemic AL amyloidosis. We prospectively studied the clinical usefulness of cyclic VAD (vincristine, doxorubicin and dexamethasone) in patients with primary systemic AL amyloidosis who were ineligible for high-dose melphalan with autologous stem cell support. Conclusions: Cyclic VAD is a potent therapeutic option in primary systemic AL amyloidosis, but in patients with renal or cardiac dysfunction careful management for adverse events, especially body fluid retention, is necessary.
INTRODUCTION
Primary systemic AL amyloidosis is an intractable disorder caused by plasma cell dyscrasia. Amyloid fibrils, formed by degradation of immunoglobulin light chains produced by abnormal plasma cells, gradually accumulate in multiple vital organs, including the heart, kidneys and gastrointestinal (GI) tract (1) . To avoid progressive dysfunction of these organs, various chemotherapies targeting plasma cell dyscrasia have been employed for the treatment of primary systemic AL amyloidosis. Among them high-dose melphalan with autologous peripheral blood stem cell transplantation (auto-PBSCT) has been widely accepted as the most effective chemotherapy with regard to hematological response in the last decade (2) . Nevertheless, this treatment has the disadvantage of high mortality ascribable to subclinical or overt dysfunction in multiple vital organs (3, 4) . VAD (vincristine, doxorubicin and dexamethasone) is another intensive chemotherapy for primary systemic AL amyloidosis (5-7). In this study we performed cyclic VAD in Japanese patients with systemic AL amyloidosis according to criteria related to the severity of organ involvement. One half of the patients showed improvement of clinical symptoms, particularly nephrotic syndrome, after complete hematological remission, and we focus upon the clinical benefits and adverse effects of cyclic VAD.
PATIENTS AND METHODS

Patients
Eight patients with primary systemic AL amyloidosis (4 men and 4 women; age range, 45 to 71 years; mean, 60.4±8.8 years), who were selected according to criteria reported by Gono et al (8), were enrolled in this study. None of the patients had received any medical treatment for plasma cell dyscrasia at enrollment. To detect amyloid deposition, alkaline Congo red staining was performed in more than 2 biopsied tissues, and in at least one of these specimens immunohistochemical staining was carried out using different antibodies to ALκ, ALλ, amyloid A, transthyretin and β2 microglobulin in order to confirm it as AL type (9). Multiple myeloma was excluded by a serum M-protein level of lower than 3.0 g/dl, plasma cells less than 10% of the total number of nucleated cells in the bone marrow and no osteolytic lesions on X-ray examinations according to the diagnostic criteria proposed by the International Myeloma Working Group (10). The percentage of plasma cells in the bone marrow was examined on smear specimens treated with Wright-Giemsa staining. To identify M-protein in serum and urine, immunofixation was performed in all the patients, and other information was weeks until disappearance of M-protein from both serum and urine on immunofixation, which was defined as complete hematological remission, as long as there were no serious complications. Interferon-α was used at a dose of 3 MIU/week as a maintenance therapy after achieving complete hematological remission. M-protein was investigated on immunofixation at 3-to 6-month intervals after its disappearance. When M-protein reappeared in either serum or urine, readministration of VAD was actively considered.
Informed consent was obtained from all the patients before starting VAD.
Evaluation of therapeutic and toxic effects
Therapeutic effects of cyclic VAD were evaluated in terms of amyloidosis-related organ involvement, particularly renal function, and performance status of the patients.
Because almost all the patients in this study showed nephrotic syndrome, we employed daily protein excretion in urine as well as total protein and albumin in serum as a therapeutic marker of renal involvement. Serum levels of brain natriuretic peptide Southwestern Oncology Group (SWOG) criteria were used for evaluating performance status of the patients (12). Toxic effects were also assessed during and after the chemotherapy. Survival curves were constructed by Kaplan-Meier's method, depending on whether the patients achieved complete hematological remission or not. In these curves starting and end points were set at commencement of therapy and death, respectively.
Statistics
A log-rank test was employed for detecting a statistically significant difference between survival curves. A p-level less than 0.05 was considered to be statistically significant. Commercially available statistics software was used for data analysis (StatView for Macintosh, Abacus Concepts, Berkeley, CA, USA).
RESULTS
Hematological response
Clinical profiles of the patients are shown in Table 1 in conjunction with the disappearance of M-protein in these 4 patients, and remained within almost normal levels for 4 years after cyclic VAD therapy (Fig. 1A) .
The remaining 4 patients (cases 5 to 8) showed serious adverse events ascribable to VAD, such as encephalopathy, glucocorticoid-induced fluid retention and worsening of renal and heart failure, and became unable to continue this therapy before the disappearance of M-protein. At cessation of VAD therapy, M-protein was detectable on immunofixation in these 4 patients, but the FLC κ/λ ratio was within normal limits in cases 6 and 8.
Survival curves
The patients were classified into remission (cases 1 to 4) and non-remission (cases 5 to 8) groups. Kaplan-Meier's survival curves of the 2 patient groups are shown in Fig.   2 . The fifty-percent survival period was 7.0±2.0 months for the non-remission group, while it could not be calculated for the remission group because all the patients are still alive. The numbers of patients alive 300 days after commencement of therapy were 4 in the remission group and only 1 in non-remission. Causes of death in the non-remission group were congestive heart failure in case 5 and uremia in cases 6 and 7. Case 8 in the non-remission group is still alive, but hemodialysis had to be started 330 days after commencement of VAD.
Therapeutic outcomes
Therapeutic outcomes in the remission group are shown in Fig. 1 . Cases 1, 2 and 4
showed improvement of nephrotic syndrome with an increase in serum levels of total protein and albumin and a decrease of more than 50% in urinary protein excretion 1 year after VAD. Serum levels of BNP (normal <20 pg/ml) decreased from 84.9 pg/ml and 407.8 pg/ml to 38.0 pg/ml and 207.6 pg/ml in cases 2 and 4, respectively, 1 year after VAD. Nevertheless, no obvious change was seen in other cardiac indices, including the thickness of IVS, FS and TMF E/A, even 4 years after VAD. Performance status of the remission group was grade 1 or 2, and did not change during and after VAD. All patients in the non-remission group showed rapid worsening of performance status in parallel with an increase in urinary protein excretion and a decrease in serum albumin (data not shown). No patient showed any symptoms ascribable to polyneuropathy before or after cyclic VAD. The most notable point concerning adverse effects of VAD in our study is that corticosteroid-induced fluid retention was much more frequently seen than previously thought. Six patients in our study (75%) showed obvious corticosteroid-induced fluid retention. Among them, 4 had to discontinue cyclic VAD therapy before achieving complete hematological remission because of adverse events, such as intestinal pseudo-obstruction and congestive heart failure ascribable to an excess of body fluid. These 6 patients were considered to have more severe impairment of renal and/or cardiac function before starting VAD with regard to serum BNP, 24 hr creatinine clearance and daily protein excretion compared with the remaining 2 patients.
As overt or subclinical visceral organ involvement often exists in patients with primary systemic AL amyloidosis, intensive management of body fluids is necessary during and after cyclic VAD therapy, particularly when marked hypoalbuminemia due to nephrotic syndrome and/or cardiac dysfunction are present. Cyclic VAD is risky in the advanced stage of primary systemic AL amyloidosis, and the enrollment criteria we employed in this study may be helpful in selecting patients eligible for this intensive chemotherapy (8).
In conclusion, cyclic VAD therapy is effective for approximately 50% of patients with primary systemic AL amyloidosis, although corticosteroid-induced fluid retention frequently occurs as an adverse effect, particularly in those with severe nephrotic syndrome and/or cardiac dysfunction. This therapy should be actively considered as a therapeutic option when high-dose melphalan with auto-PBSCT is inappropriate because of advanced age or vital organ involvement. Solid line: the remission group (n=4), broken line: the non-remission group (n=4).
Censored patients are ticked along the survival curves. 
